PHENYLephrine in 0.9 sodium chloride, 400 mcg /10 mL, (40 mcg/mL), 10 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6007-1
Published August 9, 2023 · Recall initiated: July 17, 2023
Summary
FDA records drug Class II recall D-1078-2023, published August 9, 2023 and initiated July 17, 2023. Recalling firm: Central Admixture Pharmacy Services Inc; Status: Terminated; Reported quantity: 16,971 syringes; Lot: Lot: 17-270510, 17-270512, Exp. 7/16/2023; 17-270665, 17-270699, Exp. 7/18/2023; 17-270812, Exp. 7/19/2023; 17-271062, 17-271063, 17-271064, 17-271065, Exp. 7/24/2023; 17-271350, 17-271357, 17-271421, 17-271422, Exp. 7/30/2023; 17-271836, 17-271848, Exp. 8/6/2023; 17-271890, Exp. 8/7/2023; 17-271943, 17-271954, 17-271958, 17-271962, Exp. 8/8/2023; 17-272162, 17-272174, 17-272175, 17-272176, 17-272177, Exp. 8/13/2023; 17-272444, 17-272456, 17-272473, Exp. 8/16/2023; 17-272717, 17-272721, 17-272732, Exp. 8/21/2023; 17-273550, 17-273565, 17-273579, 17-273580, Exp. 9/5/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of assurance of sterility: Lack of validation data for sanitization cycles
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Distributor
- Nationwide in the USA
- Lot
- Lot: 17-270510, 17-270512, Exp. 7/16/2023; 17-270665, 17-270699, Exp. 7/18/2023; 17-270812, Exp. 7/19/2023; 17-271062, 17-271063, 17-271064, 17-271065, Exp. 7/24/2023; 17-271350, 17-271357, 17-271421, 17-271422, Exp. 7/30/2023; 17-271836, 17-271848, Exp. 8/6/2023; 17-271890, Exp. 8/7/2023; 17-271943, 17-271954, 17-271958, 17-271962, Exp. 8/8/2023; 17-272162, 17-272174, 17-272175, 17-272176, 17-272177, Exp. 8/13/2023; 17-272444, 17-272456, 17-272473, Exp. 8/16/2023; 17-272717, 17-272721, 17-272732, Exp. 8/21/2023; 17-273550, 17-273565, 17-273579, 17-273580, Exp. 9/5/2023.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDATotal Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, (patient specific), Compound Volume 416.8 mLAugust 12, 2026
- FDAHYDROmorphone in 0.9% sodium chloride, 6 mg/30 mL, (0.2 mg/mL), 30 mL Syringe, Rx only, CAPS, CentralOctober 11, 2023
- FDAfentaNYL, 5,000 mcg/100 mL, (50 mcg/mL), 100 mL Bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935October 11, 2023
- FDAfentaNYL, 100 mcg/2 mL, (50 mcg/mL), 3 mL Syringe, Rx only, Repackaged by CAPS Inc., 7935 Dunbrook Road, SuiteOctober 11, 2023
- FDAPHENYLephrine in 0.9 sodium chloride, 800 mcg /10 mL, (80 mcg/mL), 10 mL Syringe, Rx only, CAPS, Inc., 7935August 9, 2023
- FDAfentaNYL in 0.9% sodium chloride, 10 mcg/1 mL, (10 mcg/mL), 3 mL Syringe, Rx only, Central Admixture PharmacyAugust 9, 2023
Questions about this recall
Was PHENYLephrine in 0.9 sodium chloride, 400 mcg /10 mL, (40 mcg/mL), 10 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6007-1 recalled?
Yes. FDA published recall D-1078-2023 on August 9, 2023. Reported hazard: Lack of assurance of sterility: Lack of validation data for sanitization cycles
What should I do if I have this product?
Voluntary: Firm initiated · Letter